BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 58 resultados LastUpdate Última actualización 19/10/2021 [22:17:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   por página


HUMAN-DERIVED ANTI-Aβ MONOCLONAL ANTIBODY AND APPLICATION THEREOF

NºPublicación: CN113508133A 15/10/2021

Solicitante:

长春金赛药业有限责任公司

CN_111518207_A

Resumen de: WO2020156220A1

The present invention relates to the technical field of antibody drugs, and particularly relates to a human-derived anti-Aβ monoclonal antibody and application thereof. The human-derived anti-Aβ monoclonal antibody provided by the present invention can promote the phagocytosis of Aβ by a macrophage, protecting nerve cells from the toxicity of Aβ, having a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice; the invention can be used for treating and diagnosing diseases and conditions related to amyloidosis, such as Alzheimer's disease.

traducir

HUMANIZED ANTI-AΒ MONOCLONAL ANTIBODY AND USE THEREOF

NºPublicación: CN113508131A 15/10/2021

Solicitante:

长春金赛药业有限责任公司

CN_111518205_A

Resumen de: WO2020156221A1

The present invention relates to the technical field of antibody drugs, and in particular, to a humanized anti-Aβ monoclonal antibody and use thereof. The humanized anti-Aβ monoclonal antibody provided in the present invention can inhibit polymerization of Aβ monomer, can promote phagocytosis of Aβ by macrophages, can protect neural cells from Aβ toxicity, and can be used for treating and diagnosing diseases and conditions related to amyloidosis, such as Alzheimer's disease.

traducir

HUMANIZED ANTI-Aβ MONOCLONAL ANTIBODY AND APPLICATION THEREOF

NºPublicación: CN113508132A 15/10/2021

Solicitante:

长春金赛药业有限责任公司

AU_2020214135_A1

Resumen de: WO2020156222A1

Provided are a humanized anti-Aβ monoclonal antibody and application thereof. The humanized anti-Aβ monoclonal antibody provided can inhibit the polymerization of Aβ monomers, protect nerve cells from the toxicity of Aβ, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

traducir

NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE IN HUMAN

NºPublicación: CN113508300A 15/10/2021

Solicitante:

曼尼托巴大学

WO_2020069621_PA

Resumen de: WO2020069621A1

The present invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease, an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment and an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease based on determining, in a sample from the subject, the level of phosphorylation in serine, tyrosine and/or threonine residues of interest in transferrin protein or in a functionally equivalent variant. The invention also relates to the use of transferrin protein or a functionally equivalent variant thereof, wherein the transferrin protein or variant is phosphorylated as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease. Finally, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in residues of interest of transferrin protein and the use of said kit.

traducir

HUMANIZED ANTIBODY

NºPublicación: US2021317197A1 14/10/2021

Solicitante:

AC IMMUNE SA [CH]
GENENTECH INC [US]

US_2020055928_A1

Resumen de: US2021317197A1

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.

traducir

SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES

NºPublicación: US2021318321A1 14/10/2021

Solicitante:

BRIGHAM & WOMENS HOSPITAL INC [US]

US_2021311039_A1

Resumen de: US2021318321A1

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

traducir

P53 peptides as markers in the diagnosis and prognosis of Alzheimer's disease

NºPublicación: AU2019432635A1 14/10/2021

Solicitante:

DIADEM S R L

Resumen de: AU2019432635A1

Disclosed are p53 peptides and their use as biomarkers in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention also provides for a diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of said p53 peptides specifically in human plasma of patients.

traducir

METHODS OF DIAGNOSING A DISEASE STATE

NºPublicación: EP3891295A1 13/10/2021

Solicitante:

UNIV LA TROBE [AU]

CN_113383090_A

Resumen de: WO2020113271A1

The present invention relates to microRNA biomarkers for the diagnosis, monitoring and therapy of neurodegenerative disorders including Parkinson's Disease, Alzheimer's Disease and prion diseases.

traducir

THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, AND ASSOCIATED BIOMARKERS BASED ON TRK-B

NºPublicación: WO2021201710A1 07/10/2021

Solicitante:

INST DE MEDICINA MOLECULAR JOAO LOBO ANTUNES [PT]
UNIV DE COIMBRA [PT]
FACULDADE DE MEDICINA DA UNIV DE LISBOA [PT]

Resumen de: WO2021201710A1

Therapeutic Agents, Pharmaceutical Compositions, and Associated Biomarkers The invention relates to the identification of pharmaceutical compositions, therapeutic agents, peptides, nucleic acids, genetic constructs, vectors, cells, and medicaments, and their use in methods of treatment. For example, the treatment of neuropathological conditions, in particular Alzheimer's disease. Furthermore, provided herein are biomarkers, methods for their use, methods of diagnosis, methods of monitoring disease progression, and methods for monitoring medicament efficacy, in particular for Alzheimer's disease.

traducir

IMPROVED METHOD OF DETECTING BIOMARKERS IN A BIOLOGICAL SAMPLE

NºPublicación: WO2021198098A1 07/10/2021

Solicitante:

UNIV ZUERICH [CH]

Resumen de: WO2021198098A1

Provided is a novel method of increasing the level of a soluble target protein in a biological sample by subjecting the sample to a protein cleavage reaction which does not affect the target protein. The target protein may be Abeta 42 and the biological sample may be a plasma sample from a subject, e.g. human subject. Together with appropriate detection means and methods such as cyclic amplification systems, the method of the present invention is particularly suitable for quantifying the minimal detectable amount of a target protein in a biological sample, which could serve as a biomarker in the diagnosis of a disease associated with the target protein. In particular, such disease may be Alzheimer's disease.

traducir

METHODS FOR TREATING ALZHEIMER'S DISEASE

NºPublicación: WO2021195750A1 07/10/2021

Solicitante:

JEFFERIES WILFRED [CA]
SINGH CHAAHAT [CA]

Resumen de: WO2021195750A1

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.

traducir

SYSTEM AND SENSOR ARRAY

NºPublicación: US2021311039A1 07/10/2021

Solicitante:

BRIGHAM & WOMENS HOSPITAL INC [US]

US_2021318321_A1

Resumen de: US2021311039A1

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

traducir

SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES

NºPublicación: US2021311064A1 07/10/2021

Solicitante:

BRIGHAM & WOMENS HOSPITAL INC [US]

US_2021293801_A1

Resumen de: US2021311064A1

The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

traducir

METHODS FOR DETECTING DISORDERS RELATED TO CALCIUM DISCHARGE FROM INTRACELLULAR STORES

NºPublicación: US2021311075A1 07/10/2021

Solicitante:

UNIV CALIFORNIA [US]

WO_2019027884_PA

Resumen de: US2021311075A1

Provided herein are methods for determining whether a subject has an increased likelihood of having a disorder related to abnormal intracellular calcium store discharge. In some embodiments, the method is useful for determining whether the subject has an increased likelihood of having a neurodegenerative disease, skeletal muscle disease, cardiac muscle disease, autoimmune disease, cancer, diabetes, or has been exposed to an environmental pollutant. Kits are also provided herein.

traducir

SYSTEM, ASSAY AND METHOD FOR PARTITIONING PROTEINS

NºPublicación: US2021311040A1 07/10/2021

Solicitante:

BRIGHAM & WOMENS HOSPITAL INC [US]

US_2021318321_A1

Resumen de: US2021311040A1

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

traducir

USES OF TAU PHOSPHOSITES AS BIOMARKERS FOR ALZHEIMER'S DISEASE

NºPublicación: WO2021202777A1 07/10/2021

Solicitante:

GENENTECH INC [US]

Resumen de: WO2021202777A1

The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.

traducir

DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET

NºPublicación: JP2021156891A 07/10/2021

Solicitante:

ザ・ウエスト・バージニア・ユニバーシティー・ボード・オブ・ガバナース・オン・ビハーフ・オブ・ウエスト・バージニア・ユニバーシティー

JP_2019509500_A

Resumen de: WO2017147114A1

Methods of detecting the signature of Alzheimer's disease before the clinical onset of the disease are disclosed, such as methods of diagnosing Mild Cognitive Impairment (MCI), monitoring the progress of MCI, and predicting the time to clinical onset of AD dementia. The methods use a Biomarker Severity Score, which corresponds to output signals of one or more biomarkers chosen from AD Index, Morphometric Imaging, and PKC Epsilon Biomarkers. Also disclosed are methods of screening for a compound useful for treating MCI or for preventing the clinical onset of AD dementia, as well as methods of evaluating or monitoring the therapeutic benefit of an agent for treating MCI or preventing the clinical onset of AD dementia.

traducir

COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT FOR NEUROLOGICAL DISEASES

NºPublicación: US2021311076A1 07/10/2021

Solicitante:

UNIV VIRGINIA PATENT FOUNDATION [US]

WO_2020018461_PA

Resumen de: US2021311076A1

In some embodiments herein, methods, compositions, and uses for countering the effects of aberrant meningeal lymphatic drainage and/or modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease associated with aberrant meningeal lymphatic drainage are described. Modulating lymphatic vessels, or countering the effects of aberrant meningeal lymphatic drainage, in accordance with some embodiments, are used to diagnose, treat, prevent, or ameliorate symptoms of neurodegenerative diseases such as Alzheimer's disease (AD) and dementia. Methods of diagnosing and monitoring the progression of neurological diseases are also provided.

traducir

PEPTIDES AND ANTIBODIES FOR DETECTING CHANGES IN ALZHEIMER'S DISEASE BRAIN AND METHODS OF USE THEREOF

NºPublicación: US2021299283A1 30/09/2021

Solicitante:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST [US]

WO_2018094076_PA

Resumen de: US2021299283A1

The present invention is based on the seminal discovery of a panel of targeting peptides and antibodies that can recognize AD brains at different stages of the disease, starting from early to advanced stage. The peptide probes described here are unique in the field and can be expected to advance understanding on early neurodegenerative changes associated with AD and improve the therapeutic outcomes by early detection and intervention in AD. Further, the invention provides antibodies that can be used to treat AD.

traducir

COMPOSITIONS AND METHODS RELATED TO THE METHYLATION OF HISTONE H1.0 PROTEIN

NºPublicación: US2021302429A1 30/09/2021

Solicitante:

AELAN CELL TECH INC [US]

US_2019322729_A1

Resumen de: US2021302429A1

Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

traducir

ADRENOMEDULLIN (ADM) FOR DIAGNOSIS AND/OR PREDICTION OF DEMENTIA AND ANTI-ADRENOMEDULLIN BINDER FOR USE IN THERAPY OR PREVENTION OF DEMENTIA

NºPublicación: US2021302440A1 30/09/2021

Solicitante:

SPHINGOTEC GMBH [DE]

JP_2021513077_A

Resumen de: US2021302440A1

Subject matter of the present invention is a method for diagnosing dementia, or determining the risk of getting dementia in a subject that does not have dementia, or monitoring therapy or monitoring or guiding intervention in a subject that has dementia, or monitoring therapy or monitoring or guiding preventive intervention in a subject that is at risk of getting dementia.

traducir

RGO-BASED BIOSENSOR, MANUFACTURING METHOD OF SAME, AND DETECTION METHOD FOR BIOMATERIAL

NºPublicación: JP2021526223A 30/09/2021

Solicitante:

エックスワイジプラットホームインクXYZPLATFORMINC.

US_2021239646_A1

Resumen de: WO2019231224A1

A reduced graphene oxide (RGO)-based biosensor according to the present invention comprises: a source electrode and a drain electrode formed on a substrate; a RGO channel formed between the source electrode and the drain electrode; a PDMS chip for supplying a reaction solution to the RGO channel; a passivation layer for sealing so as to prevent the reaction solution being supplied through the PDMS chip from coming in contact with the source electrode and the drain electrode; and a gate electrode. In particular, the passivation layer consists of an SU-8 photoresist, and the gate electrode is configured to come in direct contact with the reaction solution and perform liquid phase driving. By constituting the passivation layer with SU-8, the reaction solution can be supplied through the PDMS chip in a convenient and stable manner. Due to the liquid phase driving of the gate electrode, a field effect transistor (FET)-type biosensor can be implemented which can be operated at a gate voltage of about -1.0 V to 1.0 V and exhibits high sensitivity.

traducir

IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

NºPublicación: IL249925A 30/09/2021

Solicitante:

ABBVIE DEUTSCHLAND [DE]

AU_2021200575_A1

Resumen de: WO2016005328A2

The invention relates to immunogenic products based on muteinamyloid β(Aβ) amino acid sequences, in particular to oligomers of Aβ muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.

traducir

EMPTY POROUS PARTICLES FOR USE IN TREATMENT, PREVENTION AND/OR POSTPONEMENT OF DEGENERATION OF NEURODEGENERATIVE DISEASES, NEURONS AND GLIA.

NºPublicación: CN113454456A 28/09/2021

Solicitante:

纳诺洛吉卡股份公司

AU_2020257990_A1

Resumen de: WO2020212418A1

The present invention relates to empty porous particles having a diameter between 0.1 and 1000 µm, as measured by e.g. SEM, for use in diagnosis, prevention and/or postponement of neurodegenerative diseases, or for prevention and/or postponement of degeneration of neurons and glia. The invention also relates to a method of identifying biomarkers for use in diagnosis.

traducir

NOVEL COMPOUNDS FOR DIAGNOSIS

Nº publicación: JP2021525742A 27/09/2021

Solicitante:

エーシー・イミューン・エス・アー

US_2021252175_A1

Resumen de: WO2019234243A1

The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, a- synuclein, A-syn, α-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.

traducir

Página1 de 3 nextPage por página

punteroimgVolver